FDA Adverse Event Injury Summary report: N

THERASPHERE Y-90

MDR report key: 21198926 · Received January 21, 2025

Report

Report Number
2124215-2024-84218
Event Type
Injury
Date Received
January 21, 2025
Date of Event
September 11, 2024
Report Date
May 21, 2026
Manufacturer
BOSTON SCIENTIFIC CORPORATION
Product Code
NAW
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
CH
Reporter Occupation
PHYSICIAN
Health Professional
Yes

Narratives

Additional Manufacturer Narrative · 0

D3, MANUFACTURER ZIP/POSTAL: GU9 8QL.

Description of Event or Problem · 0

IT WAS REPORTED THAT THE PATIENT HAD SYMPTOMS THAT WERE TREATED WITH PRESCRIPTION MEDICATION. ON (B)(6) 2024, THE SUBJECT WAS RANDOMIZED (THERASPHERE ARM) IN THE MANDARIN STUDY (MAIN PHASE) WITH THE PLANNED TREATMENT TYPE WAS UNI-LOBAR TREATMENT. TREATMENT WITH THERASPHERE WAS PERFORMED ON (B)(6) 2024; 99MTC-MAA ANGIOGRAM WAS PERFORMED, AND TARGET VOLUME WAS 624 CM3 AND 14.73 GBQ WAS ADMINISTERED THROUGH 1 VIAL. TOTAL ACTIVITY OF THERASPHERE DELIVERY TO LUNG WAS 0.17 GBQ. RADIATION DOSE TO PERFUSED LIVER TISSUE, AND DOSE TO PERFUSED TARGET TUMOR TISSUE WAS DETAILS WERE NOT AVAILABLE AT THE TIME OF REPORTING. A RE-TREATMENT WITH THERASPHERE WAS PERFORMED ON (B)(6) 2024 WITH THE PLANNED TREATMENT TYPE WAS SELECTIVE TREATMENT. TARGET VOLUME WAS 177.94 CM3 AND 5.96 GBQ WAS ADMINISTERED THROUGH 1 VIAL. TOTAL ACTIVITY OF THERASPHERE DELIVERY TO LUNG WAS 0.183 GBQ AND TOTAL ACTIVITY OF THERASPHERE DELIVERY TO PERFUSED LIVER TISSUE 2.167 GBQ. RADIATION DOSE TO PERFUSED LIVER TISSUE WAS 593 GY AND RADIATION DOSE TO LUNGS WAS 9.1GY. ON (B)(6) 2024, SUBJECT EXPERIENCED MALAISE, ANOREXIA, AND NAUSEA. NO CORRECTIVE ACTION WAS TAKEN TO TREAT THE EVENT OF MALAISE; HOWEVER, MEGESTROL ACETATE DISPERSIBLE TABLETS WERE ADMINISTERED TO TREAT ANOREXIA AND BOTH ONDANSETRON HYDROCHLORIDE TABLETS AND ESOMEPRAZOLE MAGNESIUM ENTERIC-COATED TABLETS WERE ADMINISTERED TO TREAT NAUSEA.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
620924 THERASPHERE Y-90 MICROSPHERES RADIONUCLIDE NAW BOSTON SCIENTIFIC CORPORATION 2499393

Patients

Seq Age Sex Outcome Treatment
1